Children whose mothers took antiepileptic drugs (AEDs) while pregnant are at increased risk of early development issues, according to a new study published in Epilepsia, a journal published by Wiley on behalf of the International League Against Epilepsy (ILAE). Results of the study suggest that children exposed to AEDs in the womb were at risk for difficulties with motor development, language skills, social skills, and autistic traits compared to children whose mothers did not take anti-seizure medications.
Medical evidence suggests that epilepsy is fairly common in women of childbearing years, with the use of AEDs during pregnancy ranging from 0.2% to 0.5%. Studies have shown that children whose mothers have epilepsy are at increased risk of birth defects (congenital malformations)—mainly thought to be caused by use of older generation AEDs during pregnancy. However, there is less understanding of AED effects on cognition during development, and there is a need for more evidence regarding long-term outcomes of children exposed to anti-seizure medication in utero.
A research team, led by Dr. Gyri Veiby from Haukeland University Hospital in Bergen, Norway, studied children from the Norwegian Mother and Child Cohort Study. From 1999 through 2008, researchers recruited mothers at 13-17 weeks of pregnancy; those mothers subsequently reported motor development, language skills, social skills and autistic traits of their children at 18 months (61,351 children) and 36 months (44,147 children). Risk of adverse outcomes was determined in children according to epilepsy in the mother or father, and with or without AED exposure in the womb.
Results show that 333 children were exposed to AEDs in the womb. At 18 months of age, the children exposed to AEDs in utero had increased risk of abnormal gross motor skills and autistic traits. Analysis of AED-exposed children at 36 months revealed an increase of abnormal scores for gross motor skills, sentence skills, and autistic traits compared to unexposed children.
Further analysis determined that AED-exposed children had increased risk of birth defects compared to children not exposed to the drugs in utero. Importantly, no increased risk of developmental delays was found in children born to women with epilepsy who did not use AED during pregnancy; children of fathers with epilepsy generally scored within the normal ranges for early childhood development.
"Our study—a unique large-scale, population-based study on early developmental outcomes in offspring of parents with epilepsy—confirms that children exposed to anti-seizure medications in the womb had lower scores for key developmental areas than children not exposed to AEDs," concludes Dr. Veiby. "Exposure to valproate, lamotrigine, carbamazepine or multiple anti-seizure medications was linked to adverse developmental outcomes."
The authors stress the importance of optimal seizure control during pregnancy that balances possible adverse effects on the baby's brain development. They suggest future research examine the effects of specific AEDs on fetal development, and whether these effects continue from early childhood into school-age and adulthood.
This study is published in Epilepsia. Media wishing to receive a PDF of the article may contact email@example.com.
Full citation: "Exposure to Antiepileptic Drugs in Utero and Child Development—A Prospective Population-Based Study." Gyri Veiby, Anne K. Daltveit, Synnve Schjølberg, Camilla Stoltenberg, Anne-Siri Øyen, and Stein E. Vollset, Bernt A. Engelsen and Nils E. Gilhus. Epilepsia; Published Online: July 18, 2013 (DOI: 10.1111/epi.12226).
URL Upon Publication: http://doi.wiley.com/10.1111/epi.12226
Author Contact: Media wishing to speak with Dr. Veiby may contact the press office at Haukeland University Hospital.
About the Journal
Epilepsia is the leading, most authoritative source for current clinical and research results on all aspects of epilepsy. As the journal of the International League Against Epilepsy, subscribers every month will review scientific evidence and clinical methodology in: clinical neurology, neurophysiology, molecular biology, neuroimaging, neurochemistry, neurosurgery, pharmacology, neuroepidemiology, and therapeutic trials. For more information, please visit http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1528-1167.
About the International League Against Epilepsy
The International League Against Epilepsy (ILAE) is the world's preeminent association of physicians and health professionals working toward a world where no person's life is limited by epilepsy. Since 1909 the ILAE has provided educational and research resources that are essential in understanding, diagnosing and treating persons with epilepsy. The ILAE supports health professionals, patients, and their care providers, governments, and the general public worldwide by advancing knowledge of epilepsy.
Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.
Founded in 1807, John Wiley & Sons, Inc. (NYSE: JWa, JWb), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's website can be accessed at http://www.wiley.com.